Disagreement about FDA nanotech oversight

Advocacy groups and drug firms face off at the first open meeting of the FDA Nanotechnology Task Force

Ted Agres
Oct 10, 2006
The U.S. Food and Drug Administration (FDA) needs greater authority and financial resources to properly regulate nanotechnology materials in drugs, biologics, food, cosmetics and other products, many academics and representatives of environmental and consumer groups said at the first open meeting of the FDA Nanotechnology Task Force on Tuesday. Representatives of business groups and drug companies generally disagreed, saying FDA's existing regulatory authority is adequate to deal with the emerging field, despite the fact that there are currently no FDA regulations that specifically address nanomaterials.The nanotechnology task force was formed in August to help determine how the agency should regulate nanomaterials, especially for safety. Nearly 40 presenters and 300 observers attended the open meeting on the campus of the National Institutes of Health in Bethesda, MD. The nanotechnology industry is expected to grow to $2.6 trillion in manufactured goods by 2014, according to Lux Research. Last year, nanotech...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?